"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...
Pharmacokinetics and Metabolism
EDECRIN (ethacrynic acid) acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since EDECRIN (ethacrynic acid) inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, EDECRIN (ethacrynic acid) is effective in many patients who have significant degrees of renal insufficiency (see WARNINGS concerning deafness). EDECRIN (ethacrynic acid) has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.
The electrolyte excretion pattern of ethacrynic acid varies from that of the thiazides and mercurial diuretics. Initial sodium and chloride excretion is usually substantial and chloride loss exceeds that of sodium. With prolonged administration, chloride excretion declines, and potassium and hydrogen ion excretion may increase. EDECRIN (ethacrynic acid) is effective whether or not there is clinical acidosis or alkalosis.
Although EDECRIN (ethacrynic acid) , in carefully controlled studies in animals and experimental subjects, produces a more favorable sodium/potassium excretion ratio than the thiazides, in patients with increased diuresis excessive amounts of potassium may be excreted.
Onset of action is rapid, usually within 30 minutes after an oral dose of EDECRIN (ethacrynic acid) or within 5 minutes after an intravenous injection of SODIUM EDECRIN (ethacrynic acid) . After oral use, diuresis peaks in about 2 hours and lasts about 6 to 8 hours.
The sulfhydryl binding propensity of ethacrynic acid differs somewhat from that of the organomercurials. Its mode of action is not by carbonic anhydrase inhibition.
Ethacrynic acid does not cross the blood-brain barrier.
Last reviewed on RxList: 7/3/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Edecrin Information
Edecrin - User Reviews
Edecrin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.